Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00889200 · ClinicalTrials.gov registry record · Phase 4
Eszopiclone Treatment & Cortisol Responsivity
A Phase 4 study of Insomnia, sponsored by Butler Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT00889200 is a Phase 4 study of Insomnia that has completed, run by Butler Hospital. The registered enrollment target is 12 participants, below the 170-participant average among 151 other Insomnia trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00889200, a Phase 4 study of Insomnia, has completed, sponsored by Butler Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This study was designed to use a sensitive neuroendocrine probe, the Dexamethasone/Corticotropin-Releasing Hormone (DEX/CRH) test, in a sample of healthy adults with insomnia. The primary aim was to assess cortisol reactivity before and after long-term (6 weeks) administration of eszopiclone. It was hypothesized that treatment with eszopiclone would result in a significant reduction in plasma cortisol response to the DEX/CRH test following treatment of insomnia with standard dose of eszopiclone.
Conditions Studied
Interventions
- DRUG eszopiclone
Study Locations (1)
Rhode Island
- Butler Hospital - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2007-05 |
| Est. Completion | 2009-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00889200
The ClinicalTrials.gov registry entry for NCT00889200 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 170-participant average among 151 other Insomnia trials with a reported enrollment target (93% lower). The listed sponsor is Butler Hospital, which has 103 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Insomnia appearing as the primary indexed condition, and to 1 intervention - of which eszopiclone is the first listed.
NCT00889200 reports 1 study location spanning 1 distinct geographic area - top geographies include Rhode Island.
Frequently Asked Questions
What is clinical trial NCT00889200 about?
NCT00889200 is a clinical study titled "Eszopiclone Treatment & Cortisol Responsivity". This study was designed to use a sensitive neuroendocrine probe, the Dexamethasone/Corticotropin-Releasing Hormone (DEX/CRH) test, in a sample of healthy adults with insomnia. The primary aim was to assess cortisol reactivity before and after long-term (6 weeks) administration of eszopiclone. It was...
What is the current status of trial NCT00889200?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 12 participants. The study started on 2007-05. Estimated completion is 2009-08.
What conditions does trial NCT00889200 study?
This clinical trial studies the following conditions: Insomnia.
What interventions are being tested in trial NCT00889200?
The interventions under investigation include: eszopiclone (DRUG).
Who is sponsoring clinical trial NCT00889200?
This trial is sponsored by Butler Hospital, which has 103 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00889200 being conducted?
This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Insomnia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Comparing Digital Therapy, Trazodone, and Daridorexant for Menopause-Related Insomnia Symptoms
RECRUITING · Phase 4
-
Enhancing Hypnotic Medication Discontinuation in Primary Care
RECRUITING · Phase 4
-
Efficacy of Suvorexant in the Treatment of Insomnia in Midlife Women With Pre-Diabetes
RECRUITING · Phase 4
-
Evaluation of a Neurostimulation Device for Insomnia: A Randomized Trial
ACTIVE NOT RECRUITING · Phase 4
-
Solriamfetol and CBT-I in Patients With Insomnia Disorder
ACTIVE NOT RECRUITING · Phase 4
-
A Pilot Study of Suvorexant for Insomnia in Parkinson Disease
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.